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Jon-Vidar Gaustad*, Trude G Simonsen, Marit N Leinaas and Einar K RofstadAbstract
Background: Antiangiogenic agents that disrupt the vascular endothelial growth factor pathway have been
demonstrated to normalize tumor vasculature and improve tumor oxygenation in some studies and to induce
hypoxia in others. The aim of this preclinical study was to investigate the effect of sunitinib treatment on the
morphology and function of tumor vasculature and on tumor oxygenation.
Methods: A-07-GFP and R-18-GFP human melanoma xenografts grown in dorsal window chambers were used as
preclinical tumor models. Morphologic parameters of tumor vascular networks were assessed from high-resolution
transillumination images, and tumor blood supply time was assessed from first-pass imaging movies recorded after
a bolus of 155 kDa tetramethylrhodamine isothiocyanate-labeled dextran had been administered intravenously.
Tumor hypoxia was assessed from immunohistochemical preparations of the imaged tissue by use of pimonidazole
as a hypoxia marker.
Results: Sunitinib treatment reduced vessel densities, increased vessel segment lengths, did not affect blood supply
times, and increased hypoxic area fractions.
Conclusion: Sunitinib treatment did not improve vascular function but induced hypoxia in A-07-GFP and R-18-GFP
tumors.
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Angiogenesis is necessary for tumors to grow beyond a
certain size, determined by the diffusion limit of oxygen
and other nutrients [1]. Several proteins that may stimu-
late or inhibit angiogenesis are produced and secreted
by tumor cells, and the rate of tumor angiogenesis is
regulated by the balance between these pro- and antian-
giogenic factors [2]. While angiogenesis is tightly con-
trolled in normal tissues and results in well-organized
vasculature, malignant tumors show aberrant angiogen-
esis which results in an abnormal tumor vasculature.
The vascular abnormalities include vessel wall abnor-
malities (i.e., incomplete or missing endothelial lining,
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reproduction in any medium, provided the orpericytes and contractile vessel wall components), and
architectural abnormalities (i.e., contour irregularities,
elongated and tortuous vessels, limited arterial supply,
loss of vessel hierarchy, existence of arterioveneous
shunts, heterogeneous vessel distribution, and increased
intervessel distances) [3-5]. The architectural abnorma-
lities collectively increase the geometric resistance
against blood flow [6,7]. The elevated geometric resist-
ance and the low and heterogeneous vessel density cause
unstable blood flow, and low and heterogeneous blood
supply [3,7]. Consequently, the abnormal tumor vascula-
ture plays a key role in the development of the hostile
tumor microenvironment, which is characterized by
hypoxia, glucose deprivation, low extracellular pH, and
high interstitial fluid pressure (IFP) [4,8]. The hostile
tumor microenvironment causes resistance to therapy
[4] and may promote malignant progression and meta-
static dissemination [9].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cluding endogenous inhibitors of angiogenesis [10,11],
monoclonal antibodies against pro-angiogenic factors
[12] or their receptors [13], and small molecule tyrosine
kinase inhibitors which may target multiple pro-
angiogenic receptors [14,15]. Antiangiogenic therapy
may inhibit tumor growth significantly when used as a
single treatment modality, but the therapeutic benefit
may be even greater when used in combination with con-
ventional treatment modalities such as ionizing radiation
and chemotherapy [16]. The mechanisms underlying the
enhanced antitumor effects of the combined treatments
may differ among the antiangiogenic agents, and have not
been determined conclusively.
It has been suggested that antiangiogenic treatment
can normalize the tumor vasculature and the tumor
microenvironment and hence sensitize tumors to con-
ventional therapy [17]. Thus it has been shown that at-
tenuation of proangiogenic signaling may prune
immature blood vessels and remodel others, resulting in
more efficient vascular networks. The normalized vascu-
lar networks are characterized by greater pericyte cover-
age, lower vessel permeability, lower vessel tortuousity,
and lower vessel density [18,19]. Some studies report
decreased vessel diameters [13,18], whereas others re-
port increased vessel diameters after antiangiogenic
treatment [14,20]. Collectively, the changes in vascular
morphology are expected to reduce the geometric resis-
tance against blood flow and hence improve vascular
function in remaining vessels. In accordance with this,
antiangiogenic treatment has been reported to enhance
blood perfusion [21,22], improve tumor oxygenation
[13,19,23], lower IFP, and increase the delivery of che-
motherapeutic agents [18,22]. The normalization effect
is transient, as the tumors can switch to other angioge-
nesis pathways and thus become resistant to antiangio-
genic agents [24]. The duration of improved tumor
oxygenation is also expected to be limited because the
beneficial effects on vascular function may be balanced
by severe vascular regression by prolonged exposure to
antiangiogenic agents [17]. The optimal antitumor effect of
combination therapy is thus expected if ionizing radiation
or chemotherapy is administered within the time-window
of normalization induced by the antiangiogenic agent [17].
However, the effect of antiangiogenic therapy on tumor
oxygenation is debated, and other studies have reported
enhanced hypoxic fractions after antiangiogenic treatment
[25-27]. The effect on oxygenation may depend on tumor
model, type and dose of the antiangiogenic agent, and may
vary with time.
Sunitinib is a small molecule tyrosine kinase inhibitor
which targets vascular endothelial growth factor recep-
tors 1–3 (VEGFR-1, -2, and -3), platelet-derived growth
factor receptors α-β (PDGFR-α and PDGFR-β), stem cellgrowth factor receptor (c-KIT), and fms-like tyrosine
kinase receptor 3 (FLT 3), with potent antiangiogenic
and antitumor activity [28]. The clinical efficacy of suni-
tinib has been demonstrated for patients with gastro-
intestinal stromal tumors (GIST) or metastatic renal cell
carcinoma (RCC) [29,30]. However, studies investigating
whether sunitinib treatment can normalize tumor vascu-
lature are scarce, and whether sunitinib treatment can
improve tumor oxygenation is currently unknown.
Therefore, the aim of this study was to investigate the ef-
fect of sunitinib treatment on the morphology and func-
tion of tumor vasculature, and on tumor oxygenation.
For this purpose human melanoma xenografts grown in
dorsal window chambers were examined by intravital
microscopy techniques, and were subjected to immuno-
histological examination. We report that sunitinib treat-
ment significantly reduced vessel density, did not
improve vascular function, and induced tumor hypoxia.
Methods
Mice
Adult (8–10 weeks of age) female BALB/c nu/nu mice
were used as host animals for dorsal window chamber
preparations. The mice were bred at our institute and
maintained under specific pathogen-free conditions at
constant temperature (24–26°C) and humidity (30–50%).
After implantation of dorsal window chambers, the mice
were kept at a temperature of 32°C and a humidity of
60-70%. The animal experiments were approved by the
Norwegian National Animal Research Authority and
were done according to the Interdisciplinary Principles
and Guidelines for the Use of Animals in Research,
Marketing, and Education (New York Academy of
Sciences, New York, NY).
Cells and multicellular spheroids
A-07 and R-18 human melanoma cells [31] were constitu-
tively transfected with green fluorescence protein (GFP) by
lipofection. The transfected cells (A-07-GFP and R-18-
GFP) used in the present experiments were obtained from
our frozen stock and grown as monolayers in RPMI 1640
(25 mM HEPES and L-glutamine) supplemented with 13%
bovine calf serum, 250 μg/mL penicillin, 50 μg/mL strepto-
mycin, and 700 μg/mL (A-07-GFP) or 2200 μg/mL (R-18-
GFP) genetecin. Multicellular spheroids were produced by
seeding approximately 106 cells in 30 mL medium in plas-
tic tissue culture flasks coated with a thin layer of 1% agar
(Oxoid Limited, Hampshire, United Kingdom). The flasks
were agitated (10 periods per minute) for 2 h using a tilting
platform, and aggregates of approximately 50 μm in diam-
eter were formed. The spheroids were then allowed to
grow in coated culture flasks before implantation in win-
dow chambers (liquid-overlay culture technique) [32]. Cells
and spheroid cultures were incubated at 37°C in a
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twice a week.
Anesthesia
Window chamber implantation and intravital micros-
copy examinations were carried out with anesthetized
mice. Fentanyl citrate (Janssen Pharmaceutica, Beerse,
Belgium), fluanisone (Janssen Pharmaceutica), and mida-
zolam (Hoffmann-La Roche, Basel, Switzerland) were
administered intraperitoneally in doses of 0.63 mg/kg,
20 mg/kg, and 10 mg/kg, respectively. After surgery, the
mice were given a single injection of buprenorphine
(Temgesic; Schering-Plough, Brussels, Belgium) intrape-
ritoneally in a dose of 0.12 mg/kg to relieve pain.
Window chamber preparations
Window chambers were implanted into the dorsal skin
fold as described previously [33]. Briefly, the chamber
consisted of two parallel frames, and after implantation,
the frames sandwiched an extended double layer of skin.
Before the chamber was implanted, a circular hole with
a diameter of approximately 6.0 mm was made in one of
the skin layers. A plastic window with a diameter of
6.0 mm was attached to the frame on the surgical side
with a clip to provide visual access to the fascial side of
the opposite skin layer. Tumors were initiated by
implanting spheroids or tumor specimens with a dia-
meter of 200 to 400 μm onto the exposed skin layer.
Sunitinib treatment
Sunitinb L-malate (LC Laboratories, Woburn, MA,
USA) was dissolved in hydrochloric acid (1.0 molar ratio
of sunitinib), polysorbate 80 (0.5%; Sigma-Aldrich,
Schnelldorf, Germany), polyethylene Glycol 300 (10%;
Sigma-Aldrich, Schnelldorf, Germany), sodium hydro-
xide (to adjust pH to 3.5), and sterile water. Mice were
treated with 20 or 40 mg/kg/day sunitinib or vehicle for
4 or 8 days, by oral administration.
Intravital microscopy
Intravital microscopy was performed before initiation of
sunitinib treatment (day 0), and 1, 2, and 4 days after the
start of treatment (short-term treatment), or before, and 2,
4, 6 and 8 days after the start of treatment (prolonged
treatment). The mice were kept in a specially constructed
holder that fixed the window chamber to the microscope
stage during intravital microscopy. The body core
temperature was kept at 37 to 38°C by using a hot-air gen-
erator. Imaging was performed by using an inverted fluor-
escence microscope equipped with filters for green and red
light (IX-71; Olympus, Munich, Germany), a black and
white CCD camera (C9300-024; Hamamatsu Photonics,
Hamamatsu, Japan), and appropriate image acquisition
software (Wasabi; Hamamatsu Photonics). Tumorvasculature was visualized by using transillumination and
filters for green light, and tumor vascular networks were
mapped by recording 1-4 single frames with a×4 objective
lens resulting in a field of view of 3.80×3.80 mm2 and a
pixel size of 3.7 × 3.7 μm2. To study the function of tumor
vasculature, first-pass imaging movies were recorded after
a 0.2 mL bolus of 50 mg/mL tetramethylrhodamine
isothiocyanate-labeled dextran (Sigma-Aldrich, Schnell-
dorf, Germany) with a molecular weight of 155 kDa was
injected into the lateral tail vein. First-pass imaging movies
were recorded at a frame rate of 22.3 frames per second by
using a×2 objective lens, resulting in a time resolution of
44.8 ms, a field of view of 5.97×5.97 mm2, and a pixel size
of 7.5 × 7.5 μm2. All recordings were stored and analyzed
offline. Tumor size (i.e., tumor area) was calculated from
the number of pixels showing GFP fluorescence.
Analysis of vascular morphology
Two-dimensional projected vascular masks were pro-
duced manually from transillumination images recorded
with the × 4 objective lens. Interstitial distance (i.e., the
distance from a tumor pixel outside the vascular mask
to the nearest pixel within the vascular mask) and vessel
diameter were computed from the vascular masks [34].
Vessel density (i.e., total vessel length per mm2 tumor
area) was calculated from skeletons of vascular masks.
Vessel density of small or large vessels was calculated
from skeletons of vascular masks only showing vessels
with a diameter smaller or larger than 15 μm. The ana-
lysis of vascular morphology is illustrated for a represen-
tative tumor in Figure 1. This figure shows high-
resolution transillumination images (Figure 1A-B), the
vascular mask (Figure 1C), the skeleton of the vascular
mask (Figure 1D), and color-coded vessel diameter
superimposed on the vascular mask (Figure 1E). Vessel
segment length and vessel tortuosity were calculated
from ~50 randomly selected vessel segments. Vessel tor-
tuosity (T) was defined as T= (SL – S) 100% / SL, where
SL represents the segment length (i.e., the distance be-
tween the branching points along the vessel) and S
represents the shortest distance between the branching
points (i.e., the distance between the branching points
along a straight line), as illustrated in Figure 1F. Change
in vessel diameter was assessed by manually measuring
the diameter of the same vessel segments on subsequent
days.
Analysis of vascular function
Two-dimensional projected vascular masks were pro-
duced from the movies recorded with the × 2 objective
lens as described previously [34]. Blood supply time
(BST) images were produced by assigning a BST value to
each pixel of the vascular masks. The BST of a pixel was
defined as the time difference between the frame
Figure 1 Analysis of vascular morphology. A, intravital microscopy image of a representative untreated R-18-GFP tumor. Tumor area is
delineated by a solid black line. B, intravital microscopy image of the region highlighted in A. C, vascular mask. D, skeleton of the vascular mask.
Vessels with diameter >15 μm are shown in red and vessels with diameter < 15 μm are shown in green. E, color-coded vessel diameter
superimposed on the vascular mask. Color bar, vessel diameter scale in μm. Figures C-E refer to the tumor region shown in B. F, sketch of vessel
segment. Vessel segment length (SL; red) was defined as the distance between branching points along the vessel, whereas vessel tortuosity (T)
was defined as T = (SL – S) 100% / SL, where SL represents the vessel segment length and S represents the shortest distance between the
branching points (S; green).
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and the frame showing maximum fluorescence intensity
in the main tumor supplying artery, as described in de-
tail previously [35].
Immunohistochemical detection of tumor hypoxia,
microvessels, vascular basement membrane, and
pericytes
The tumors were resected immediately after the last intra-
vital microscopy examinations and fixed in phosphate-
buffered 4% paraformaldehyde. Pimonidazole [1-[(2-
hydroxy-3-piperidinyl)-propyl]-2-nitroimidazole], admi-
nistered as described previously [36], was used as hypoxia
marker, CD31 was used as marker for endothelial cells,
collagen IV was used as marker for vascular basement
membrane, and α-smooth muscle actin (α-SMA) was used
as marker for pericytes. Immunohistochemistry was done
by using a peroxidase-based indirect staining method [36].
An anti-pimonidazole rabbit polyclonal antibody (gift
from Prof. J.A. Raleigh, Department of Radiation Oncol-
ogy, University of North Carolina School of Medicine,
Chapel Hill, NC), an anti-CD31 rabbit polyclonal antibody
(Abcam, Cambridge, United Kingdom), an anti-collagen
IV rabbit polyclonal antibody (Abcam), or an anti-α-SMA
rabbit polyclonal antibody (Abcam) was used as primary
antibody. Diaminobenzidine was used as chromogen, and
hematoxylin was used for counterstaining. Hypoxic areafractions were determined by image analysis. Number of
microvessel profiles per mm2 of tumor tissue (#/mm2)
was scored manually and used as parameter for micro-
vascular density.
Statistical analysis
Statistical comparisons of data were carried out by the
Student’s t test when the data complied with the condi-
tions of normality and equal variance. Under other con-
ditions, comparisons were done by nonparametric
analysis using the Mann-Whitney rank sum test. The
Kolmogorov-Smirnov method was used to test for nor-
mality, and the Levene’s test was used to test for equal
variance. Probability values of P < 0.05, determined from
two-sided tests, were considered significant. The statis-
tical analysis was performed by using the SigmaStat stat-
istical software (SPSS Science, Chicago, IL, USA).
Results
Short-term sunitinib treatment did not affect tumor growth
Mice were divided in groups with matched tumor size to
receive sunitinib treatment or no treatment (vehicle).
Sunitinib treatment was started 6 (A-07-GFP) or 12 days
(R-18-GFP) after tumor initiation. At these time points,
defined as day 0, A-07-GFP and R-18-GFP tumors were
of similar size (Figure 2), and had developed vascular net-
works (Figure 3). During the short treatment period,
Figure 2 Short-term sunitinib treatment did not affect tumor
growth. Tumor size versus time for untreated and sunitinib-treated
A-07-GFP (A-B) and R-18-GFP tumors (C). Points, means of 6-10
tumors; bars, SEM. Dotted line indicates time of treatment start.
Tumors were initiated 6 (A-07-GFP; A-B) or 12 days (R-18-GFP; C)
before start of treatment.
Gaustad et al. BMC Cancer 2012, 12:388 Page 5 of 15
http://www.biomedcentral.com/1471-2407/12/388sunitinib-treated tumors did not differ from untreated
tumors in size regardless of whether A-07-GFP tumors
were treated with 20 mg/kg/day sunitinib (P > 0.05;
Figure 2A), A-07-GFP tumors were treated with 40 mg/kg/day sunitinib (P > 0.05; Figure 2B), or R-18-GFP
tumors were treated with 40 mg/kg/day sunitinib
(P > 0.05; Figure 2C).
Sunitinib treatment reduced vessel density
To investigate effects of sunitinib treatment on vascular
morphology, mice treated with sunitinib or vehicle were
submitted to intravital microscopy. Sunitinib treatment
reduced vessel density in both A-07-GFP and R-18-GFP
tumors. This is shown qualitatively in Figure 3 which
shows representative intravital microscopy images of an
untreated A-07-GFP tumor (Figure 3A), an A-07-GFP
tumor treated with sunitinib (Figure 3B), an untreated
R-18-GFP tumor (Figure 3C), and an R-18-GFP tumor
treated with sunitinib (Figure 3D). To quantify these
qualitative observations, vascular masks were produced
and vessel densities and interstitial distances were calcu-
lated. Sunitinib-treated tumors had significantly lower
vessel densities and significantly higher interstitial dis-
tances than untreated tumors (Figure 4A). The
sunitinib-induced reduction in vessel densities was more
pronounced for A-07-GFP tumors than for R-18-GFP
tumors. For sunitinib-treated A-07-GFP-tumors, the
density of small vessels decreased more than the density
of large vessels (Table 1), implying that sunitinib treat-
ment selectively pruned small vessels. For sunitinib-
treated R-18-GFP tumors, the densities of small and
large vessels were similarly reduced.
Sunitinib treatment increased vessel segment length, but
did not affect vessel tortuosity
To investigate the effect of sunitinib treatment on indi-
vidual vessels, vessel segment lengths and vessel tortuos-
ities were quantified. Sunitinib-treated tumors had
significantly longer segment lengths than untreated
tumors (Figure 4B), whereas sunitinib treatment did not
affect vessel tortuosities (P > 0.05; data not shown). The
sunitinib-induced effect on segment lengths was more
pronounced for A-07-GFP tumors than for R-18-GFP
tumors.
Sunitinib treatment increased median vessel diameter but
inhibited vessel diameter increase in remaining vessels
Sunitinib-treated A-07-GFP tumors showed higher me-
dian vessel diameters than untreated A-07-GFP tumors,
whereas sunitinib-treated R-18-GFP tumors did not dif-
fer from untreated R-18-GFP tumors in median vessel
diameter (Figure 4C). To investigate changes in vessel
diameters of remaining vessels, the diameter was mea-
sured in the same vessels on subsequent days. Ves-
sels in untreateted tumors showed an increase in
vessel diameter from day 1 to day 2, and from day 1
to day 4. Vessels in A-07-GFP tumors treated with
20 mg/kg/day sunitinib showed similar changes in
Figure 3 Images of tumor vascular networks. Representative intravital microscopy images from day 0, 1, 2, and 4 of an untreated A-07-GFP
tumor (A), an A-07-GFP tumor treated with 40 mg/kg/day sunitinib (B), an untreated R-18-GFP tumor (C), and an R-18-GFP tumor treated with
40 mg/kg/day sunitinib (D). Tumor area is delineated by a solid black line.
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tumors treated with 40 mg/kg/day sunitinib showed
lower increases in vessel diameters than untreated
tumors (Figure 4C). Consequently, the increase in
median vessel diameter did not reflect increases in
the vessel diameters of remaining vessels, but rather
a selective pruning of small vessels.Immunohistochemical investigations showed that
sunitinib treatment did not affect vascular basement
membrane and pericyte-coverage and confirmed that
sunitinib treatment reduced vessel density
Histological sections of A-07-GFP and R-18-GFP window
chamber tumors were stained for CD31, collagen IV, or
α-SMA to visualize endothelial cells, vascular basement
Figure 4 Sunitinib treatment affected vascular morphology. Vessel density, and median interstitial distance versus time (A), median vessel
segment length versus time (B), median vessel diameter versus time, and change in vessel diameter versus time interval (C) for untreated and
sunitinib-treated A-07-GFP and R-18-GFP tumors. P-values are indicated in the panels where statistical tests revealed significant or borderline
significant differences between untreated and sunitinib-treated tumors. Points, means of 6-9 tumors; bars, SEM.
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Table 1 Reductions in vessel density after short-term
sunitinib treatment
All vessels Small vessels Large vessels
A-07-GFP 20 mg/kg/day 1.71 2.11 1.40
A-07-GFP 40 mg/kg/day 2.31 2.99 1.75
R-18-GFP 40 mg/kg/day 1.33 1.31 1.37
Data refer to fold reduction in vessel density in sunitinib-treated tumors
compared with untreated tumors after 4 days of treatment (i.e., vessel density
in untreated tumors / vessel density in sunitinib-treated tumors). Vessel
densities refer to the vessel density of all tumor vessels, only small tumor
vessels (vessels with diameter < 15 μm), or only large tumor vessels (vessels
with diameter > 15 μm).
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showed vascular basement membrane and were covered
with pericytes (Figure 5A-B). Long bands with positive α-
SMA staining originating in CD31-positive vessel walls
were observed in A-07-GFP tumors, revealing large net-
works of pericytes in these tumors. In contrast, most ves-
sels in R-18-GFP tumors did not show vascular basement
membrane, and pericytes were only found adjacent to
microvessels (Figure 5C-D). Sunitinib-treated tumors did
not differ from untreated tumors in vascular basement
membrane or pericyte-coverage and, consequently, the dif-
ferences in vessel maturation between A-07-GFP and R-
18-GFP tumors were observed regardless of whether un-
treated or sunitinib-treated tumors were considered.
Immunohistochemical preparations stained for CD31 con-
firmed that sunitinib treatment significantly reduced vessel
density (Figure 5E). Moreover, significant correlations were
found between microvascular density assessed by immuno-
histochemistry and vessel density assessed by intravital mi-
croscopy in both A-07-GFP and R-18-GFP tumors
(Figure 5F-G).
Sunitinib treatment did not affect BST
To investigate the effect of sunitinib treatment on the
function of tumor vasculature, first-pass imaging movies
were recorded, and BST images and BST frequency dis-
tributions were produced. BST was not affected by suni-
tinib treatment. This is shown qualitatively in Figure 6,
which shows representative BST images and the corre-
sponding BST frequency distributions from day 2 and 4
of an untreated A-07-GFP tumor (Figure 6A), an A-07-
GFP tumor treated with sunitinib (Figure 6B), an un-
treated R-18-GFP tumor (Figure 6C), and an R-18-GFP
tumor treated with sunitinib (Figure 6D). The black re-
gion in the sunitinib-treated A-07-GFP tumor
(Figure 6B) reflects an avascular region which contains
hypoxic tumor tissue. Figure 7 shows BST for all tumors
included in the short-term treatment experiments, illus-
trating that untreated and sunitinib-treated tumors did
not differ in BST on either day 2 or 4, regardless of
whether A-07-GFP tumors were treated with 20 mg/kg/
day sunitinib (P > 0.05; Figure 7A), A-07-GFP tumorswere treated with 40 mg/kg/day sunitinib (P > 0.05;
Figure 7B), or R-18-GFP tumors were treated with
40 mg/kg/day sunitinib (P > 0.05; Figure 7C).
Sunitinib treatment induced hypoxia
To investigate the effect of sunitinib treatment on tumor
hypoxia, tumors were resected and submitted to histo-
logical examination immediately after the last intravital
microscopy imaging session. Untreated A-07-GFP
tumors did not show hypoxic regions whereas sunitinib-
treated A-07-GFP tumors showed multiple hypoxic
regions (Figure 8A). The hypoxic regions co-localized
with avascular regions or regions with very low vessel
density, and were found in both central and peripherial
parts of sunitinib-treated A-07-GFP tumors (Figure 8A;
right). 3 out of 6 untreated R-18-GFP tumors and 7 out
of 8 sunitinib-treated R-18-GFP tumors showed scat-
tered hypoxic regions (Figure 8B). R-18-GFP tumors did
not show avascular regions, and the hypoxic regions
reflected low overall vessel densities. The hypoxic area
fractions were significantly higher in sunitinib-treated A-
07-GFP tumors than in untreated A-07-GFP tumors,
and a non-significant trend towards higher hypoxic area
fractions in sunitinib-treated R-18-GFP tumors com-
pared to untreated R-18-GFP tumors was observed
(Figure 8C).
Prolonged sunitinib treatment reduced tumor growth
In a separate experiment, A-07-GFP tumors were treated
with 40 mg/kg/day sunitinib or vehicle for 8 days. By day
6, untreated tumors grew close to the window chamber
boundaries, and mice bearing untreated tumors were sacri-
ficed to avoid growth restriction by the chamber prepara-
tions. Sunitinib-treated tumors were significantly smaller
(P=0.041; Figure 9A), and were allowed to grow for two
more days. The prolonged sunitinib treatment further
reduced vessel densities, and increased interstitial distances
(Figure 9B-C), but did not affect BST (Figure 9D). Our ex-
perimental model did not allow evaluation of longer treat-
ment periods. The treatment was started immediately after
tumors were vascularized, and the experiments were ended
before the tumors outgrew the window chambers. Suniti-
nib treatment completely inhibited vascularization if the
treatment was started before tumors were vascularized
(data not shown).
Discussion
In the present work, A-07-GFP and R-18-GFP mela-
noma xenografts grown in dorsal window chambers
were used as preclinical models. It has previously been
shown that intradermal A-07 and R-18 xenografts retain
several characteristic features of the original patient
tumors, including histological appearance, angiogenic
potential, and vessel density [31]. Moreover, intradermal
Figure 5 Immunohistochemical detection of microvessels, vascular basement membrane, and pericytes. A-D, representative
immunohistochemical preparations stained with anti-CD31 antibody, anti-collagen IV antibody, or anti-α-smooth muscle actin (α-SMA) antibody
to visualize endothelial cells, vascular basement membrane, and pericytes. The images refer to an untreated A-07-GFP tumor (A), an A-07-GFP
tumor treated with 40 mg/kg/day sunitinib (B), an untreated R-18-GFP tumor (C), and an R-18-GFP tumor treated with 40 mg/kg/day sunitinib
(D). E, microvascular density in untreated and sunitinib-treated A-07-GFP and R-18-GFP tumors. Points, means of 4 tumors; bars, SEM. F-G,
microvascular density assessed by immunohistochemistry versus vessel density assessed by intravital microscopy in A-07-GFP (F) and R-18-GFP (G)
tumors. Points, individual tumors; curves, curves fitted to the data by linear regression analysis.
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substantially in angiogenic potential, vessel density,
growth rate, and oxygenation status [31,36,37]. These
differences were maintained when A-07-GFP and R-18-
GFP tumors were grown in dorsal window chambers
despite the transfection with GFP, the confinement of
tumor growth by the chamber preparations, the smallsize of the tumors, and the elevated temperature during
tumor growth. Consequently, A-07-GFP and R-18-GFP
tumors grown in dorsal window chambers should be ap-
propriate models for investigating the effect of sunitinib
treatment on tumor vasculature and oxygenation.
Tumors were treated with two different doses of suni-
tinib in the current study. Both sunitinib doses have
Figure 6 BST images and frequency distributions. Representative blood supply time (BST) images and the corresponding BST frequency
distributions from day 2 and 4 of an untreated A-07-GFP tumor (A), an A-07-GFP tumor treated with 40 mg/kg/day sunitinib (B), an untreated R-
18-GFP tumor (C), and an R-18-GFP tumor treated with 40 mg/kg/day sunitinib (D). Color bars, BST scale in seconds; vertical lines, median BST.
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tions in athymic mice to inhibit VEGFR and PDGFR
phosphorylation in xenografts of human melanoma,
human glioma, and human colon carcinoma [38].
Lower sunitinib doses have been shown to result in
insufficient plasma concentrations and no inhibitionof VEGFR and PDGFR phosphorylation in the same
xenograft models [38]. Moreover, the higher sunitinib
dose (40 mg/kg/day) has been shown to reduce ves-
sel density and improve vascular function in human
glioma xenografts [14]. The two sunitinib doses
should therefore be well suited to evaluate the effect
Figure 7 Sunitinib treatment did not affect BST. Median blood
supply time (BST) at day 2 and 4 for untreated and sunitinib-treated
A-07-GFP and R-18-GFP tumors. Points, individual tumors; horizontal
lines, mean BST.
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http://www.biomedcentral.com/1471-2407/12/388of sunitinib treatment on tumor vasculature and
tumor oxygenation.
The morphology of tumor vasculature was assessed by
mapping tumor vascular networks with high-resolution
transillumination images and filters for green light. In
these images only vessels with erythrocytes can be seen
and, consequently, the morphological analysis was based
on vessels with erythrocytes as opposed to dysfunctionalvessels with plasma only. The function of tumor vascula-
ture was assessed by using a novel first-pass imaging
method which involves recording movies of the dynamic
distribution of a fluorescent vascular tracer after an
intravenous bolus injection [33,35,39]. From the
recorded first-pass imaging movies, BST images and cor-
responding BST frequency distributions were produced.
We have previously shown that the BST-assay is highly
reproducible, sufficiently sensitive to detect gradients in
BST along vessel segments, and sufficiently sensitive to
indentify the majority of tumor vessels [33,35,39].
It has previously been shown that A-07 and R-18 cells
express and secrete VEGF-A and interleukin-8 (IL-8),
and that the angiogenic activity can be significantly
reduced by inhibiting VEGF-A in both xenograft lines
[40]. The secretion rate of VEGF-A and IL-8 has been
shown to be higher for A-07 cells than for R-18 cells
and, in addition, A-07 cells have been shown to express
and secrete basic fibroblast growth factor (bFGF)
whereas R-18 cells do not secrete this factor [40]. In the
present work, we show that sunitinib treatment signifi-
cantly reduced vessel densities in both A-07-GFP and R-
18-GFP tumors. The sunitinib-induced antiangiogenic
effects were more pronounced for A-07-GFP tumors
than for R-18-GFP tumors, and these differences pro-
bably reflected differences in the angiogenic profiles.
Treatment-induced reductions in vessel densities are
expected to reduce tumor growth. In the present study,
prolonged sunitinib treatment significantly reduced
tumor growth, whereas short-term sunitinib treatment
did not affect tumor size. This observation illustrates
that effects on tumor size generally are delayed com-
pared to the effects on tumor vasculature after antian-
giogenic treatment [41].
Sunitinib treatment did not affect BST and, conse-
quently, improved vascular function was not observed in
the current study. Narrow, elongated, and tortuous
tumor vessels are expected to elevate the geometric re-
sistance to blood flow, and a potential increase in vessel
diameter, decrease in vessel segment length, or reduction
in vessel tortuosity is expected to enhance tumor blood
flow [6,7]. In the present study, we observed increased
vessel segment lengths and unchanged vessel tortuosities
after sunitinib treatment, and the remaining vessels in
sunitinib-treated tumors showed similar or smaller
increases in vessel diameter than vessels in untreated
tumors. The effects on vascular morphology are thus in
accordance with the observation that sunitinib treatment
did not improve vascular function. Reduction in vessel
density combined with no improvement of vascular
function is expected to impair oxygen supply. In accord-
ance with this, sunitinib treatment induced hypoxia in
A-07-GFP and R-18-GFP tumors. Interestingly, A-07-
GFP tumors differed substantially from R-18-GFP
Figure 8 Sunitinib treatment induced hypoxia. A-B, representative immunohistochemical preparations stained for pimonidazole to visualize
hypoxia and intravital microscopy images of an untreated A-07-GFP tumor (A, left), an A-07-GFP tumor treated with 40 mg/kg/day sunitinib (A,
right), an untreated R-18-GFP tumor (B, left), and an R-18-GFP tumor treated with 40 mg/kg/day sunitinib (B, right). Tumor area is delineated by a
solid black line in intravital microscopy images. C, hypoxic area fraction for untreated and sunitinib-treated A-07-GFP and R-18-GFP tumors. Points,
individual tumors; horizontal lines, mean hypoxic area fraction.
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http://www.biomedcentral.com/1471-2407/12/388tumors in vessel maturation. Our study thus illustrates
that sunitinib treatment fails to improve vascular func-
tion in melanoma xenografts with both high and low
degrees of vessel maturation.
Sunitinib-induced improvement of vascular function
has been reported in a preclinical study of human gli-
oma xenografts [14]. In that study, increased red blood
cell velocities were observed 2, 4, and 6 days after the
start of sunitinib treatment. The time points where
improved vascular function was observed in that study
thus correspond well to the time points where BST wasassessed in our study (2, 4, and 8 days after the start of
sunitinib treatment). Consequently, the lack of improved
vascular function observed in our study was unlikely to
be due to inadequate observation time points.
Treatment with anti-VEGF-A or anti-VEGFR-2 anti-
body has improved vascular function and tumor oxygen-
ation in some preclinical models [13,19,23]. The same
antibodies have failed to improve vascular function and
increased hypoxic fractions or have not affected tumor
oxygenation in other preclinical models [19,25]. Simi-
larly, sunitinib-induced blockade of VEGFR and PDGFR
Figure 9 Prolonged sunitinib treatment reduced tumor growth. A, tumor size versus time for untreated and sunitinib-treated A-07-GFP
tumors. Points, means of 4 tumors; bars, SEM. Curves, curves fitted to the data by regression analysis. Dotted vertical line indicates time of
treatment start. Tumors were initiated 6 days before start of treatment. B-C, vessel density (B), and interstitial distance (C) versus time for
untreated and sunitinib-treated A-07-GFP tumors. Points, means of 4 tumors; bars, SEM. D, median blood supply time (BST) for untreated and
sunitinib-treated A-07-GFP tumors. Points, individual tumors; horizontal lines, mean BST. P-values are indicated in the panels where statistical tests
revealed significant differences between untreated and sunitinib-treated tumors (A-D).
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http://www.biomedcentral.com/1471-2407/12/388has been reported to improve vascular function in
human glioma xenografts [14], whereas the current
study shows that sunitinib treatment does not improve
vascular function in human melanoma xenografts. Con-
sequently, whether antiangiogenic treatment improves
vascular function, does not reflect whether the antian-
giogenic agent blocks PDGFR in addition to VEGFR, but
more likely reflects differences in tumor models.
In addition to improve tumor blood supply and
oxygenation, antiangiogenic agents have also been
reported to reduce vessel permeability and lower
tumor IFP in preclinical models. These effects have
collectively been referred to as vascular normalization
[17,18]. Moreover, increased hypoxic fractions,
reduced vessel permeability, and lowered tumor IFP
have been observed simultaneously after antiangio-
genic treatment [27]. This observation suggests that
improved tumor oxygenation, normalized vessel per-
meability, and normalized tumor IFP may not neces-
sarily occur in parallel temporal windows [27].
Consequently, although sunitinib treatment did not
improve blood supply and oxygenation in A-07-GFP
and R-18-GFP tumors, we cannot rule out thepossibility that sunitinib treatment may normalize
vessel permeability and tumor IFP in these tumor
models.
Sunitinib has been shown to prolong progression-free
and overall survival in patients with imatinib-refractory
GIST and metastatic RCC in clinical phase III trials, and
has been approved by the US Food and Drug Adminis-
tration for these indications [29,30]. However, the
tumors eventually become unresponsive to sunitinib,
and the benefits in progression-free and overall survival
are measured in months. Treatment regimes that com-
bine sunitinib with ionizing radiation, different che-
motherapeutic agents, or other antiangiogenic agents
may enhance and prolong the effects of sunitinib, and
clinical studies that evaluate such combinations are on-
going [42].
The current study and previously reported preclinical
studies suggest that antiangiogenic treatment improves
vascular function and tumor oxygenation in some cli-
nical tumors, and induces hypoxia in others. Neoadju-
vant antiangiogenic therapy may enhance the effect of
ionizing radiation or chemotherapy in clinical tumors
where antiangiogenic treatment improves vascular
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http://www.biomedcentral.com/1471-2407/12/388function. The feasibility of this strategy has been demon-
strated in preclinical studies where maximal antitumor ef-
fect of ionizing radiation was achieved when tumors were
irradiated within the time period when tumor oxygenation
was improved by antiangiogenic treatment [13,23]. On the
other hand, in clinical tumors where antiangiogenic treat-
ment induces hypoxia, neoadjuvant antiangiogenic therapy
is expected to reduce the effect of ionizing radiation or
chemotherapy [4,8]. Consequently, antiangiogenic agents
should not be considered as neoadjuvant therapy in com-
bination with radiation or chemotherapy in such tumors.
Whether it is possible to predict if antiangiogenic treat-
ment can improve vascular function in a specific tumor is
currently unknown. The effect of antiangiogenic treatment
on tumor vasculature and on tumor oxygenation should
thus be monitored closely if antiangiogenic treatment is
considered as neoadjuvant therapy.
Conclusions
Sunitinib treatment reduced vessel density but did not
improve vascular function in A-07-GFP and R-18-GFP
human melanoma xenografts. The sunitinib treatment
increased hypoxic fractions and, consequently, sunitinib
used as neoadjuvant therapy may reduce the effect of
ionizing radiation or chemotherapy in clinical tumors
similar to the A-07-GFP and R-18-GFP human mela-
noma xenografts.
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